Replies to post #81826 on Anavex Life Sciences Corp (AVXL)

[A_Good_Day_2]

Thanks for the info.

I think you may be right. When the 6-month data came out many were disappointed at the "leveling off" of efficacy with patients who were dual therapy. I thought just the opposite. Maybe the other med was competing or interfering with 2-73. I thought 2-73 would continue to do better on its own. Maybe that's just what happened!

Hope it turns out as good as it appears!

[A_Good_Day_2]

Can't find the interview where Missling says they are focusing on mono therapy. Can anyone point me in the right direction?

Thanks for the help!